Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 401

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 401
---
9. Gilead’s ownership then diluted to25.35% at December 31, 2023 and at December 31, 2024, due to one capital increase resulting from the exercise of subscription rights under employee subscription right plans in the course of 2023.

F-64

Table of Contents

The presumption of significant influence is also confirmed by the fact that Gilead has the right, for as long as it holds more than20% of Galapagos’ share capital, to appointtwoInvestor Board Designees to Galapagos’ Board of Directors, out of a total ofnine.
The following table details our relation with Gilead:
December 31,
2024 2023 2022
──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
(Euro, in thousands)
Trade and other receivables (1) € 2,268 € 5,198 € 7,877
Trade and other payables - 585
Year ended December 31,
2024 2023 2022
(Euro, in thousands)
Revenues recognized related to the performance obligation for the drug discovery platform € 230,182 € 230,242 € 230,423
Revenues recognized related to the filgotinib performance obligation (2) 26,041 429,439 174,432
Royalty income related to the commercialization of filgotinib 10,604 9,466 10,726
Cost reimbursements related to the development of GLPG1690 (3) 128 299 411
Cross charges from and to Gilead relating to filgotinib (4) - 3,643 ( 2,374)
Costs (-)/deduction of costs relating to our 50/50 profit/(cost) share mechanism (5)
included in sales and marketing expenses - - 31
included in research and development expenditure - - ( 31)
Purchase of raw materials, semi-finished products and finished products of Jyseleca € - € - € 13,539
(1) Consisting on December 31, 2024 mainly of a royalties receivable of €2.2million, consisting on December 31, 2023 of filgotinib development cost sharing receivables of €2.5million and royalties receivables of €2.4million, consisting on December